The future role of CD4 cell count for monitoring antiretroviral therapy

The Lancet Infectious Diseases

Volumn 15, Issue 2, 2015, Pages 241-247

  Ford, Nathan ^a,b   Meintjes, Graeme ^b   Pozniak, Anton ^c   Bygrave, Helen ^d   Hill, Andrew ^e   Peter, Trevor ^f   Davies, Mary Ann ^b   Grinsztejn, Beatriz ^g   Calmy, Alexandra ^h   Kumarasamy, N ⁱ   Phanuphak, Praphan ^j   deBeaudrap, Pierre ^k   Vitoria, Marco ^a   Doherty, Meg ^a   Stevens, Wendy ^l   Siberry, George K ^m  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f CLINTON HEALTH ACCESS INITIATIVE   (United States)

^g INSTITUTO OSWALDO CRUZ   (Brazil)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^j THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^k INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^l UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^m EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CONSULTATION; COST CONTROL; DRUG MONITORING; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PATIENT CARE; PRIORITY JOURNAL; VIRAL LOAD TESTING; VIRUS LOAD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PROCEDURES; UTILIZATION;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; HIV INFECTIONS; HUMANS;

EID: 84921025303     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70896-5     Document Type: Note

References (61)

1. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987, 316:61-66.
2. Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA 1987, 257:331-334.
3. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172.
4. Phillips AN, Lee CA, Elford J, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991, 337:389-392.
5. Fauci AS, Macher AM, Longo DL, et al. NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984, 100:92-106.
6. Pedersen C, Gerstoft J, Tauris P, et al. Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS 1990, 4:1111-1116.
7. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994, 7:287-295.
8. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
9. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Recomm Rep 1998, 47:43-82. Department of Health and Human Services and Henry J.
10. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach 2002, WHO, World Health Organization, Geneva.
11. Harrigan R Measuring viral load in the clinical setting. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:34-40.
12. Rutherford GW, Anglemyer A, Easterbrook PJ, et al. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS 2014, 28:161-169.
13. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr 2013, 64:74-78.
14. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach 2013, WHO, World Health Organization, Geneva.
15. African Society of Laboratory Medicine. African Society of Laboratory Medicine. Expert Consultation on Viral Load Monitoring in African HIV Treatment Programmes; Cape Town, South Africa; April 18-20, 2013.
16. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/muL and HIV-1 suppression?. Clin Infect Dis 2013, 56:1340-1343.
17. Girard PM, Nelson M, Mohammed P, Hill A, van Delft Y, Moecklinghoff C Can we stop CD4 testing in patients with HIV-1 RNA suppression on antiretroviral treatment? Analysis of the ARTEMIS trial. AIDS 2013, 27:2759-2763.
18. Reynolds S, Sempa J, Kiragga A, et al. Is CD4 monitoring needed among Ugandan clients achieving virologic response to treatment? 2014 Conference on Retroviruses and Opportunistic Infections; Boston, USA; March 3-6 March, 2014. Abstract 56.
19. Vitoria M, Vella S, Ford N Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 2013, 8:12-18.
20. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach 2013, WHO, World Health Organization, Geneva.
21. Vitoria M, Vella S, Ford N Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 2013, 8:12-18.
22. Meintjes G MG, Boulle A, Conradie F, et al. Guidelines for antiretroviral therapy in adults by the Southern African HIV Clinicians Society. SAJHIVMED 2012, 13:114-133.
23. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach 2010, WHO, World Health Organization, Geneva.
24. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012, 26:1663-1672.
25. Hyle EP, Sax PE, Walensky RP Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med 2013, 173:1746-1748.
26. UNITAID Diagnostic Technology Landscape Report 2014, UNITAID, UNITAID, Geneva. 4th edn.
27. Roberts T, Bygrave H, Fajardo E, Ford N Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc 2012, 15:17324.
28. Rowley CF Developments in CD4 and viral load monitoring in resource-limited settings. Clin Infect Dis 2014, 58:407-412.
29. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
30. Nelson LJ, Beusenberg M, Habiyambere V, et al. Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines. AIDS 2014, 28:S217-S224.
31. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services HHS Panel on Antiretroviral Guidelines for Adults and Adolescents, (accessed Nov 12, 2013). http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
32. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2010, 51:855-864.
33. Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. Aids 2011, 25:851-855.
34. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
35. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
36. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856-862.
37. Suthar AB, Granich R, Mermin J, Van Rie A Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012, 90:128-138.
38. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach 2006, WHO, World Health Organization, Geneva.
39. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013, 27:1403-1412.
40. Phillips AN, Youle M, Lampe F, et al. CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. AIDS 2002, 16:1073-1075.
41. Whitlock GG, Ahmed N, Benn P, Edwards S, Waters L Stop routine CD4 monitoring in HIV-infected patients with fully suppressed virus and CD4 >=350 cells/ml. Clin Infect Dis 2013, 57:327-328.
42. Ford N, Stinson K, Davies M-A, et al. Is it safe to drop CD4 monitoring among virologically suppressed patients: a cohort evaluation from Khayelitsha, South Africa. AIDS 2014, 28:2003-2005.
43. Davies M-A, Rabie H, Fatti G, et al. Can CD4 monitoring in virologically suppressed children on antiretroviral therapy be reduced of stopped? 18th International Workshop on HIV Observational Databases; Sitges, Spain; March 27-29, 2014. Abstract 85.
44. Gaur AH, Flynn PM, Bitar W, Liang H Optimizing frequency of CD4 assays in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2013, 29:418-422.
45. Kanters S, Nachega J, Funk A, et al. CD4 T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis. Antivir Ther 2014, 19:31-39.
46. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007, 45:183-192.
47. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010, 24:614-617.
48. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005, 41:361-372.
49. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007, 370:407-413.
50. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010, 53:70-77.
51. Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010, 55:451-459.
52. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012, 2012:670957.
53. Carter M Six-montly CD4 cell monitoring 'unnecessary' for people doing well on HIV therapy. AIDSMAP Jan 17, 2013, (accessed Nov 1, 2014). http://www.aidsmap.com/Six-monthly-CD4-cell-monitoring-unnecessary-for-people-doing-well-on-HIV-therapy/page/2564237/.
54. Sax PE Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care?. Clin Infect Dis 2013, 56:1344-1346.
55. Wilson D, Keiluhu AK, Kogrum S, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009, 103:601-606.
56. Mocroft A, Reiss P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis 2010, 51:611-619. Opportunistic Infections Project Team of the Collaboration of Observational HIVERiE.
57. Zoufaly A, an der Heiden M, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 2011, 203:364-371.
58. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299. Antiretroviral Therapy Cohort Collaboration.
59. Bor J HA, Newell M-L, Barninghausen T Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013, 339:961-965.
60. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013, 10:e1001418.
61. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011, 155:209-216.